VEEVA SYSTEMS INC Q4 FY2025 earnings call

• The fourth quarter was strong with revenue of $721 million and non-GAAP operating income of $308 million. Full year total revenue was $2.75 billion and non-GAAP operating income was $1.15 billion.
• Significant year for Veeva with innovations across product areas and progress on AI strategy. Set 2030 revenue goal of $6 billion and announced expansion into new markets.
• Progress in clinical products like eTMF, CTMS, with expansion into broader clinical suite including study training, Site Connect, etc.
• Focus on Data Cloud, with Compass as a key opportunity, and plans for small companies.
• AI strategy with focus on specific use cases like eTMF Bot, CRM Voice Control, etc.
• Vault CRM momentum with new clients and innovation in CRM products.

In the fourth quarter, total revenue was $721 million, and for the full year, total revenue was $2.75 billion. However, there is no detailed breakdown of financial performance by specific product segments with revenue contribution percentages provided in the transcript.

• Set 2030 revenue goal of $6 billion.
• Full year margin guide is the highest ever, driven by efficiency and investment in product innovation.
• Fiscal 2026 guidance assumes no major macro changes, with subscription growth deceleration due to normalizing previous impacts and Crossix's strong prior year performance.

• Risks related to economic cycles, potential disruptions from industry changes (like tariffs, research funding), and competition.
• Uncertainties in customer decision timelines and macroeconomic impacts on contracts.

Q: Hi. Great. Good afternoon. I guess, first, congrats on the top 20 customer that went out in with Veeva in clinical after you mentioned seeing these opportunities last quarter. I wanted to ask, I think there's maybe a trend in the large pharma community to perhaps reduce procurement risk and consolidate around strategic vendors. Is that part of why these opportunities are now arising? And how do you generally think about large strategic transactions like this when thinking about what you might see in the upcoming year?

A: Hi, Joe. This is Peter. I'll take that one. I think this is really about - for this particular customer, this is really about speed just more efficient to make a combined decision for the full clinical platform in a better way to align their different clinical teams onto a shared goal and shared technology. So I didn't sense any risk avoidance in this particular case. And in general, for the top 20 pharma, they're more with us focusing on competitive advantage, speed, compliance, not really a risk avoidance. Also, there's some desire to somewhat standardize because they know in the clinical area, the more they standardize together it will make it easier for the clinical research sites they deal with. Now I wouldn't draw any particular conclusion to other customers. It is the one pattern would be we are getting more strategic with our customers as ours. We have more product solutions and more of our product solutions are proven. But each of the top 20 is going to take a different path. This is due to just where they are in their technology journey and also where they're at in their pipeline and the things they need to accomplish Q: Okay. That's great, Peter. Thank you. And then I wanted to ask just on recent industry developments, even though I think recently, there was even some news overnight just now in terms of research funding. But Veeva has always been kind of very thoughtful. I remember back when the IRA was approved, you were very early in addressing what drug price legislation might be in - I guess, along those same lines, if there are changes to indirect research funding, how do you think about potential knock-on effects over time what customers might be thinking about and then how that ultimately impacts Veeva?

A: Yes. Joe, it's Paul. And yes, we're certainly paying attention to what's happening around research funding. But I'll take your question maybe a little bit more broadly. There's certainly a lot that's happening, right? There's a lot of proposed changes across many different areas. We're seeing changes in the news daily about FDA or NIH or price negotiations. So there's a whole lot going on. It's early, right? It's a little bit early to predict exactly what the impact may or may not be. One thing I can tell you is our customers - there's really no impact that to our customer decision-making process so far. So we're not really seeing any change there. We're going to have to see how things play out, particularly as it relates to the answers. There's just a lot of factors that come into play. It's super early to predict. I guess maybe two things that I might point out for you, though, our Life Sciences is generally more resilient to economic cycles or potential changes that you're talking about, because it's an adaptable industry. They're accustomed to these kinds of changes. And then as it flows through to Veeva, our revenue tends to be more predictable, right? It's core systems, it's annual subscriptions. Projects may get delayed. But if there is disruption due to something like this, those projects typically come back. So it's early to give you a detail assessment of what the impact looks like, but it's something we're keeping our eye on closely